Mirikizumab Tops Placebo for Moderately-to-Severely Active Ulcerative Colitis
Mirikizumab more effective for inducing and maintaining clinical remission in patients with ulcerative colitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.